Objective: To perform a European sentinel surveillance study for antimicrobial resistance (AMR) in Neisseria gonorrhoeae as part of the European Surveillance of Sexually Transmitted Infections (ESSTI) Programme. Methods: From 2006 to 2008 seventeen countries participated in the AMR surveillance programme. The susceptibility of a total of 3528 consecutive isolates was tested using the agar dilution breakpoint technique or Etests for ciprofloxacin, penicillin, tetracycline, azithromycin, spectinomycin and ceftriaxone. Nitrocefin was used to detect β -lactamase activity.
INTRODUCTION
Neisseria gonorrhoeae is the causative agent of gonorrhoea, a sexually transmitted infection (STI) which continues to present a significant public health problem across Europe and Worldwide, with approximately 62 million new cases diagnosed globally each year. [1] Gonorrhoea primarily presents as a mucosal infection of the lower genital tract, which is predominantly symptomatic in men presenting as urethritis but is thought to be asymptomatic in about 50% of women. N. gonorrhoeae can ascend to the upper genital tract, if undiagnosed or inadequately treated, leading to complications such as infertility which occur more frequently in women or can invade the blood causing disseminated infections (e.g. septic arthritis, meningitis, endocarditis). Gonorrhoea is associated with an increase in the acquisition and transmission of HIV. [2] Treatment of gonorrhoea, therefore, is essential not only for individual patient management but also to intercept transmission chains and so reduce the overall disease burden. However, successful treatment of gonorrhoea is severely compromised by the propensity of N. gonorrhoeae to develop resistance to antimicrobials used for therapy, and the subsequent worldwide spread of resistant gonococci is well documented. [3] [4] [5] [6] [7] [8] Therefore, surveillance of antimicrobial resistance (AMR) for N. gonorrhoeae is of paramount importance to inform prescribing policy to ensure patients receive appropriate therapy.
The European Surveillance of Sexually Transmitted Infections (ESSTI) project was established in 2002 to develop and coordinate epidemiological and laboratory surveillance of sexually transmitted infections (STIs) in the European region in order to better inform about STI prevention, care and control. Surveillance data collected by ESSTI demonstrated that the number of cases of gonorrhoea, from 1998 to 2007, rose in Western Europe, remained steady in Central Europe and declined in the two Eastern European countries that supplied data. [9] However there was wide variation in the rate of gonorrhoea diagnoses in individual countries, for example, 0.3/100,000 in Italy to 30.8/100,000 in the United Kingdom in 2007. [9] Although this may be due to the heterogeneity in the different surveillance and laboratory systems. [9] Euro-GASP (European Gonococcal Antimicrobial Surveillance Programme), the laboratory component of ESSTI, performed the first European sentinel surveillance study for AMR in N. gonorrhoeae in 2004. [10] This initial study revealed high resistance rates to ciprofloxacin (31%) which was used by most countries for treatment at that time, and tetracycline (60%) and penicillin (21%), along with azithromycin resistance of over 5% observed for the first time. Surveillance studies are essential to demonstrate when resistance rates to antimicrobials exceed 5%, the level at which a therapeutic agent should no longer be recommended as first line therapy. [11] In addition, it is of particular importance to monitor emerging resistance to the current recommended therapy across Europe, the third generation cephalosporins. [12] Euro-GASP has subsequently performed sentinel surveillance studies in 2006 to 2008 to continue to monitor the prevalence of antimicrobial-resistant N. gonorrhoeae across Europe.
METHODS

Participating laboratories
Seventeen N. gonorrhoeae reference or specialist laboratories participated in the ESSTI N. gonorrhoeae AMR surveillance study as previously described. [ The isolates were sub-cultured once before susceptibility testing was performed. Plates were incubated for 18 -24 hours at 36 o C in 5% CO 2 and the presence of bacterial growth was recorded for each isolate. All isolates were tested for penicillinase production using the chromogenic reagent, Nitrocefin (Oxoid), following manufacturer's instructions. The ceftriaxone MIC of isolates was determined using Etests (AB bioMérieux, Solna, Sweden) according to the manufacturer's instructions.
Azithromycin MICs were determined by Etest for isolates displaying resistance by the agar dilution breakpoint technique.
The Clinical and Laboratory Standards Institute (CLSI) breakpoints for susceptibility or resistance [13] , as widely used in European countries, were used for ciprofloxacin, penicillin, tetracycline and spectinomycin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [14] were followed for azithromycin and ceftriaxone, as CLSI have not yet recommended a breakpoint for azithromycin and the lower EUCAST breakpoints for ceftriaxone ensure levels of decreased susceptibility are not under estimated. In summary, strains were categorised according to the following definitions: Ciprofloxacin resistant (MICs 
Statistical analysis
Fisher's exact test was used to assess the significance of difference between the resistance rates from 2006 to 2008. The significance of difference between all countries and countries that participated in all of the three years was assessed using
Fisher's exact test. The differences between the resistance rates of each antimicrobial between all participating countries in each year was assessed using the chi-squared test for penicillin, tetracycline and ciprofloxacin, and the Fisher's exact test was used for azithromycin and fully susceptible strains. P values less than 0.05 were categorised as significant.
Quality assurance and control
Laboratory personnel from each of the three testing centres were trained in a single centre (the HPA) to ensure consistency of technique. Quality control strains (WHO A (spectinomycin resistant), WHO G (penicillin and tetracycline resistant), WHO J (PPNG, ciprofloxacin and tetracycline resistant), and G06-1153 (azithromycin resistant clinical strain)) were included in each susceptibility testing run. To ensure consistent quality assurance (QA), two different panels of 10 strains were tested by the three centres each year using all methods and the results from all three centres were compared.
RESULTS
Isolate and patient data
A total of 3645 isolates were collected over the three year period ( Table 1 ). The age range of the patients was 6 to 81 years, with a mode and median age of 24 and 31 years respectively.
Antimicrobial susceptibility
Data from all countries for each year was combined to determine the overall resistance rates ( Figure 1 ). The list of participating countries varied slightly for each
year (Table 2 ). However, there were small, non-significant differences (Fisher's exact test p > 0.05) when the resistance rates from the countries that participated in all of the three years was compared to all countries in each of the three years (Tables 2   and 3 ). For each antimicrobial in each year there was considerable variation in the resistance rates between the countries (chi-squared and Fisher's exact test p ≤ 0.01) (Tables 2 and 3 ).
The overall level of ciprofloxacin resistance significantly increased from 42% in 2006 to 51% (Fishers exact test p < 0.001). All countries displayed more than 5% resistance to ciprofloxacin in each year tested ( Table 2) . No apparent trend for azithromycin resistance rates was evident ( Table 2) Figure 2 ).
Quality assurance
The overall concordance for the agar dilution breakpoint technique was 94% (94/100). For the agar dilution technique there were six occasions when the same category of resistance was not achieved for penicillin (n=4), ciprofloxacin (n=1) and azithromycin (n=1) for each QA isolate. However all of these six strains had a MIC on a breakpoint. There was 100% concordance for 10 strains tested by azithromycin Etest. Eighty-five percent (17/20) concordance was achieved for the 20 strains tested by ceftriaxone Etest, where the MICs differed by less than two doubling dilutions. The internal quality control strains results were within one dilution of the expected ranges. (Table 3 to be published as web-only please) antimicrobial is not an appropriate choice for use in any of the countries which participated in this study, unless isolates are known to be susceptible or local resistance rates are known to be less than 5%.
It was encouraging to note that not only were there no examples of decreasedsusceptibility to ceftriaxone over the sampling period, but there was also little change The threat of emerging resistance to third generation cephalosporins highlights the need to consider future therapeutic options. Azithromycin is not currently a recommended treatment for gonorrhoea [12] but it is proposed that it could be effective as part of a dual therapy in the treatment of pharyngeal gonorrhoea. [25;26] It is therefore important to monitor azithromycin resistance, particularly as the gonococcal population is frequently exposed to this drug as the recommended therapy for treating Chlamydia trachomatis co-infection. is required to establish a trend. Of great concern were the five isolates from Scotland and Ireland exhibiting high-level resistance to azithromycin (>256 mg/L).
This resistance phenotype in N. gonorrhoeae was first detected in Scotland in 2004, [27] and has since been reported from England and Wales, [28] Italy[29] and
Argentina. [30] Widespread dissemination of high-level azithromycin resistant strains would eliminate azithromycin as a future treatment option. While no resistance to spectinomycin, another therapeutic option, was observed in the current study, problems with availability of this drug in many European countries limits the utility of this as a therapeutic option.
Development and continuation of a European scheme for surveillance of gonococcal antimicrobial susceptibility is a significant achievement which has clear public health benefits. This is now an ongoing programme and the focus for the future will be to include more European countries and to overcome some of the acknowledged limitations of the current study such as the variability in numbers submitted from each country annually and differences in the representativeness of the selected isolates for each country. In the current study, there was no difference when the rates of resistance from the countries that participated in all of the three years were compared to all countries in each of the three years. However the overall trends may be biased by the variable number of isolates a country submits in each of the three years and the level of representativeness from each country. Further development of this programme will also focus on increasing sampling numbers from countries with high rates of gonorrhoea and on increasing the frequency of testing so changes in gonococci antimicrobial susceptibilities can be detected more rapidly. In addition, future European surveillance work will focus on ensuring the panel of antimicrobials are therapeutically relevant and have the potential for use in the future. Continued efforts to reliably link epidemiological data to the antimicrobial susceptibility data will be critical in establishing which core groups carry the burden of resistance to help focus intervention strategies.
This study has identified continued high rates of ciprofloxacin resistance, high-level azithromycin resistance and an upward ceftriaxone MIC drift in the European gonococcal population. This demonstrates that N. gonorrhoeae AMR surveillance studies are essential to inform treatment guidelines thereby preventing onward transmission and reducing patient morbidity. These studies should continue to monitor for increasing, emerging and high-level resistance, and also to help assist in the decision making process about future antimicrobials options. 
KEY MESSAGES
Longitudinal surveillance of antimicrobial resistance in gonorrhoea showed ciprofloxacin is not suitable for treatment in Europe because of continued high levels of resistance.
The emergence of high-level azithromycin resistance is of great concern as widespread dissemination of these strains would eliminate azithromycin as a future treatment option.
Ceftriaxone is an appropriate treatment for gonorrhoea in Europe as all isolates tested were susceptible.
An upward ceftriaxone MIC drift was detected in the European gonococcal population, demonstrating that this situation needs to be monitored carefully. 
